STRATEGIC MARKETING INNOVATIONS

Lobbying for TONIX PHARMACEUTICALS · Clinical-stage biopharmaceutical company

Filing 1st Quarter - Report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 16, 2026

Income

$40,000.00

What the client paid this registrant for the period.

Client based in

Massachusetts

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Lobbying activity 2

Defense

Patient access to non-opioid analgesic drug treatments. Biodefense countermeasures fundings.

Health Issues

Patient access to non-opioid analgesic drug treatments. Biodefense countermeasures fundings.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.